Brazil's Medical Cannabis Market Hits 873,000 Patients, $200M Revenue

Brazil's medical cannabis program has reached 873,000 registered patients, with the market generating nearly $200 million in annual revenue as the country's regulatory framework continues to expand.

The milestone comes ahead of Cannabis Fair 2026, scheduled for May 21-23 in São Paulo, where industry stakeholders will gather to discuss the market's rapid growth and new opportunities following recent policy changes that legalized domestic hemp cultivation.

The patient count represents significant growth for Latin America's largest cannabis market, which has evolved from importing finished products to now allowing domestic cultivation and processing. Brazil's medical program operates under a framework managed by ANVISA, the country's health regulatory agency, which has gradually loosened restrictions over the past five years.

The Regulatory Shift

The recent authorization for domestic hemp cultivation marks a turning point for Brazilian operators. Previously, companies could only import cannabis products or operate through limited research licenses. Now, Brazilian farmers and processors can cultivate hemp domestically, though THC limits remain strict—products cannot exceed 0.2% THC content.

This regulatory change positions Brazil as an emerging production hub, not just a consumer market. The country's agricultural expertise and favorable growing climate could make it competitive with established producers in Colombia and Uruguay.

Market Dynamics

The $200 million market size reflects both prescription medications and over-the-counter CBD products. Most patients access cannabis through private prescriptions, as Brazil's public health system (SUS) doesn't yet cover medical cannabis treatments—a point of ongoing advocacy by patient groups.

Pricing remains a challenge. Imported products can cost Brazilian patients $150-300 per month, making access difficult despite the growing patient registry. Domestic production could reduce costs by 40-60%, according to industry estimates.

What's Drawing International Interest

Cannabis Fair 2026 is expected to attract operators from North America and Europe looking to enter the Brazilian market. The country's population of 215 million represents the largest untapped medical cannabis market in the Americas.

But foreign companies face hurdles. Brazil requires local partnerships for cultivation and processing licenses. Import duties remain high. And the regulatory process, while improving, still moves slowly compared to more established markets.

Still, the math is compelling: if Brazil reaches even 1% patient penetration—roughly 2.1 million patients—the market could exceed $500 million annually.

What's Next

The São Paulo conference will likely focus on domestic cultivation logistics, patient access expansion, and potential regulatory reforms. Industry observers are watching whether ANVISA will expand the list of qualifying conditions or allow higher THC products for specific medical cases.

Brazil's Congress is also considering broader cannabis reform legislation, though political dynamics make passage uncertain. The medical program, however, has bipartisan support and continues expanding regardless of broader legalization debates.

---

This article is based on original reporting by hightimes.com.